The presence of LKB1 mutations can significantly impact cancer therapy. Tumors with LKB1 loss often exhibit resistance to certain therapies, including targeted therapies and immunotherapies. For instance, LKB1-deficient tumors show reduced sensitivity to drugs that target the PI3K/AKT/mTOR pathway due to compensatory metabolic pathways. Additionally, these tumors may have an altered immune microenvironment, leading to decreased efficacy of immune checkpoint inhibitors.
